Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Wuhu Nuowei Chemistry Co., Ltd
WARNING LETTER
•Wuhu Nuowei Chemistry Co., Ltd•September 6, 2024

Wuhu Nuowei Chemistry Co., Ltd – FDA Warning Letter, Sep 6, 2024

Record Details

The FDA inspected Wuhu Nuowei Chemistry Co., Ltd. from September 2-6, 2024, identifying significant Current Good Manufacturing Practice (CGMP) deviations for active pharmaceutical ingredients (APIs), rendering them adulterated under section 501(a)(2)(B) of the FD&C Act. Additionally, the drug (b)(4) was found adulterated under section 501(b) for failing compendial standards. Key violations include the failure to ensure scientifically sound specifications and test procedures for APIs, specifically (b)(4), where impurity limits exceeded USP standards and required related compound testing was omitted. The quality unit failed to exercise its responsibility to ensure CGMP compliance, notably lacking adequate stability data for API retest dates. Furthermore, the firm failed to establish adequate written procedures for cleaning equipment and its release, with cleaning validation being insufficient. These findings indicate an ineffective quality system and inadequate management oversight. The FDA placed the firm's products on Import Alert 66-40 and may refuse admission of articles. The company committed to ceasing drug production for the U.S. market and deregistered, but must clarify future intentions. A response detailing corrective actions is required within 15 working days, and engaging a qualified consultant is recommended if U.S. market manufacturing resumes.

Company
Wuhu Nuowei Chemistry Co., Ltd
Inspection date
September 6, 2024
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Francis Godwin (Director)
View Company Profile

ID · 77fa83b5-ed71-4e9b-adc1-dbbae59044fa

Violation Codes6
21 U.S.C. 351(a)(2)(B)21 U.S.C. 351(b)FD&C Act 501(a)(2)(B)FD&C Act 501(b)FD&C Act 801(a)(3)21 U.S.C. 381(a)(3)

Full citation text and observation details available on the Dashboard.

Other documents for Wuhu Nuowei Chemistry Co., Ltd
  • 483 - 2024-09-06September 6, 2024

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Wuhu Nuowei Chemistry Co., Ltd
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.